728
Participants
Start Date
October 13, 2018
Primary Completion Date
December 4, 2023
Study Completion Date
December 4, 2023
Chemotherapy combined with immunotherapy
chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors
radiotherapy
Intensity-modulated radiation therapy
Tianjin Cancer Hospital, Tianjin
Henan Cancer Hospital, Zhengzhou
Hunan Cancer Hospital, Changsha
Shanxi Cancer Hospital, Taiyuan
Sichuan Cancer Hospital, Chengdu
Sichuan Cancer Hospital and Research Institute
OTHER
Henan Cancer Hospital
OTHER_GOV
Shanxi Province Cancer Hospital
OTHER
Hunan Cancer Hospital
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
Hebei Medical University Fourth Hospital
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER